Compare Citius Pharmaceuticals Inc (CTXR) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while United Microelectronics Corp trades at $25.42 (market cap $59.23B). The key difference: United Microelectronics Corp is far larger — about 4045.8× Citius Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 1.73% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | UMC | |
|---|---|---|
Market Cap | $14.64M | $59.23B |
Sector | Health | Technology |
52-Week High | $1.82 | $28.02 |
52-Week Low | $0.53 | $6.58 |
Enterprise Value | $10.86M | $56.81B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
UMC trades at $23.46, down 3.62% over the past day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.20, exceeding expectations of $0.12, and announced a $0.41 dividend payable in August 2026. Revenue grew to $237.55 billion in 2025, though net income margin has declined from 32.1% in 2022 to 16.99% in 2025. Positive developments include mass production of silicon photonics ICs and a new 14nm eHV FinFET platform.
Outlook remains mixed with strong operational cash flow and technological advancements balanced against high valuation multiples and margin compression. Key risks include competitive pressures in semiconductor foundry markets and sensitivity to global economic cycles. Analyst consensus is cautious with 53.3% hold ratings, suggesting limited near-term upside despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
